BG
TTPH

Bellevue Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Bellevue Group’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,100
Closed -$95K – 127
2016
Q2 		$95K Hold
1,100
– – 0.02% 123
2016
Q1 		$102K Buy
+1,100
New +$110K 0.02% 127

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bellevue Group's TTPH Position: Q3 2016 in Review

Bellevue Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2016, closing a stake of 1,100 shares — an estimated $95K sold.

Bellevue Group first reported a position in TTPH in Q1 2016 and held it in 2 quarters. The position peaked at $102K in Q1 2016. 90 funds tracked by Wall St. Rank hold TTPH as of Q3 2016.

  • Bellevue Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Bellevue Group sold 1,100 Tetraphase Pharmaceuticals, Inc. shares in Q3 2016, an estimated $95K.
  • Bellevue Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2016 and held it in 2 quarters.
  • Bellevue Group's Tetraphase Pharmaceuticals, Inc. position peaked at $102K in Q1 2016.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2016.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.